Atossa Therapeutics Azioni (NASDAQ: ATOS)

Ultime notizie per Atossa Therapeutics (NASDAQ:ATOS) Azioni

ATOSSA THERAPEUTICS INC

Atossa Therapeutics

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Atossa Therapeutics Inc

Atos SE

ATOS ORIGIN SA U/ADR NEW by Atos Origin SA

Atos SE DR

Redwire (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDW#NYSE">RDW</a>) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.14) by 35.71 percent. This is a 47.06 percent increase over losses of $(0.17) per share from the same period last year. The company reported quarterly sales of $61.40 million which missed the analyst consensus estimate of $83.86 million by 26.79 percent. This is a 30.07 percent decrease over sales of $87.79 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

Redwire Q1 EPS $(0.09) Beats $(0.14) Estimate, Sales $61.40M Miss $83.86M Estimate

Redwire Q1 EPS $(0.09) Beats $(0.20) Estimate, Sales $61.40M Miss $72.17M Estimate

The 145% tariff on Chinese imports, previously imposed by President Donald Trump, has reportedly put Walmart and Target supplier&#8217;s Huntar Company Inc.&#8217;s factory in China at risk of shutting down.
What Happened: The tariff, which was effective from April 9, has caused a significant decline in orders for toys from the Huntar factory in Guangdong Province, China. The factory, a supplier of educational toys for Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) and Target Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>), has already reduced production by 60% to 70% and downsized a third of its 400 Chinese workers, reported Reuters. 
Huntar CEO Jason Cheung is now attempting to move his operations to Vietnam before the company&#8217;s funds are exhausted. The factory&#8217;s situation reflects the crisis faced by many factories in China, where approximately 80% of toys sold in the U.S. are manufactured.
The U.S.-China trade war poses risks to the sector in both countries, and Huntar, though based in the U.S., is uniquely impacted due to its operations in both markets.
Fearing factory shutdowns and unable to replace U.S. demand for key exports like toys and textiles, China returned to trade talks in Geneva, sources told Reuters. 
 Rick Woldenberg, CEO of toy company Learning Resources, stated &#8220;If nothing changes, we&#8217;ll be crippled.&#8221;
SEE ALSO: <a href="https://benzinga.com/news/25/05/45338281/trump-has-a-proven-track-record-of-being-an-absolute-failure-says-gov-tim-walz-we-dont-need-to-run-governmen" target="_blank" rel="noreferrer noopener">Trump Has A &#8216;Proven Track Record Of Being An Absolute Failure,&#8217; Says Gov. Tim Walz—&#8217;We Don&#8217;t Need To Run Government Like A Business&#8217;</a>
Why It Matters: Trump&#8217;s tariffs were designed to encourage companies to move manufacturing back to the U.S. However, Huntar&#8217;s situation illustrates why this is unlikely. Key obstacles include the shortage of facilities and skilled toy-making workers in other countries, the high cost and complexity of relocating heavy equipment, and limited time to address these challenges before funding runs out.
An April survey by the Toy Association found that over 45% of small and mid-sized U.S. toy companies believe China tariffs could force them out of business within weeks or months.
Major U.S. retailers, including Walmart and Target, have reportedly asked Chinese suppliers to <a href="https://www.benzinga.com/markets/equities/25/04/45037102/walmart-home-depot-target-push-chinese-suppliers-to-resume-shipments-agree-to-absorb-tariffs-report">resume shipments</a>, with tariffs to be absorbed by the American retailers. However, the impact of the tariffs is already being felt by toy companies. Mattel Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAT#NASDAQ">MAT</a>) announced plans to raise prices ahead of Christmas <a href="https://www.benzinga.com/trading-ideas/25/05/45227056/trumps-tariffs-hit-mattels-barbies-will-americans-pay-a-couple-of-bucks-more-as-president-predicts">due to the </a>tariffs.
On May 12, the U.S. and China agreed to a<a href="https://www.benzinga.com/markets/equities/25/05/45341884/apple-amazon-nvidia-rise-in-monday-premarket-as-us-china-agree-to-90-day-tariff-truce-neither-side-wants-a-decoupling"> temporary reduction</a> in most tariffs, marking a significant easing of trade tensions. However, the overall tariff level on China remains at 30%.
Over the past month, Walmart stock gained 2.10%, while Target Corporations rose 1.85%. 
<ul class="wp-block-list">
<li>READ MORE: <a href="https://benzinga.com/markets/cryptocurrency/25/05/45192498/bitcoins-key-level-is-96500-analyst-warns-but-heres-what-could-trigger-a-breakdown" target="_blank" rel="noreferrer noopener">Bitcoin&#8217;s Key Level Is $96,500, Analyst Warns, But Here&#8217;s What Could Trigger A Breakdown &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Economics

Markets

General

Trump's Tariffs Reportedly Push Walmart And Target Toy Suppliers To The Brink Of Closure: 'If Nothing Changes, We'll Be Crippled'

Needham analyst Kyle Peterson maintains Fair Isaac (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>) with a Buy and raises the price target from $2500 to $2575.

Price Target

Analyst Ratings

FICO

Needham Maintains Buy on Fair Isaac, Raises Price Target to $2575

In a recent interview, Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) co-founder Bill Gates expressed his views on President Donald Trump's tariffs, market turmoil, and the global tech rivalry with China.
What Happened: Gates was critical of the unpredictability surrounding U.S. economic policies, warning that it obstructs long-term business decisions. "If you&#8217;re going to build a new factory, you need to understand the policies for the next 20 years, not just the next two days or even four years," he said <a href="https://www.youtube.com/watch?v=HWHOUi5u5HU">in</a> an interview with CNN.
He underscored the risk of introducing volatility in a period already molded by <a href="https://www.benzinga.com/personal-finance/25/01/43303778/bill-gates-says-this-book-on-ai-will-change-every-industry-predicts-millions-of-jobs-will-vanish-by-2030">fast-paced advancements</a> in <a href="https://www.benzinga.com/tech/25/05/45217913/nvidias-jensen-huang-says-ai-revived-san-francisco-predicts-the-gpu-driven-revolution-will-change-every-job">artificial intelligence and labor market changes</a>. "I think it&#8217;s a bad time to interject so much uncertainty," Gates opined.
On the U.S.-China tech rivalry, Gates acknowledged that export bans have pushed China to focus its <a href="https://www.benzinga.com/news/global/25/04/44757498/chinas-bold-bet-on-an-82-billion-national-fund-targets-ai-startups-in-the-race-for-global-tech-leadership">own efforts</a>. "They&#8217;ve forced the Chinese in terms of chip manufacturing and everything to go <a href="https://www.benzinga.com/25/04/44897966/huawei-prepares-for-bulk-shipment-of-new-advanced-ai-chip-as-china-seeks-nvidia-alternatives">full speed ahead</a>," he said.
See Also: <a href="https://www.benzinga.com/news/global/25/05/45335581/trump-proposes-major-cut-in-china-tariffs-signaling-shift-in-trade-war">Trump Proposes Major Cut in China Tariffs, Signaling Shift in Trade War</a>
Why It Matters: Gates observed that the tariff and tech restrictions have only <a href="https://www.benzinga.com/tech/25/04/44970472/chinas-chip-breakthrough-without-asml-makes-chamath-palihapitiya-take-stock-of-beijings-formidable-nature-america-can-win-if">boosted China's initiatives</a> to become self-reliant. "The notion that it was going to be super unique to us—we made clear to them that they needed to make their own chips, and they&#8217;re making great progress on doing that," he said. 
Gates added that with open-source tools widely available, neither the U.S. nor China is likely to come out on top: "The AI technologies will be available to the world, and people can build on those in their own way."
Despite his concerns, Gates expressed restrained optimism about the U.S. economy. "I think there&#8217;s a lot of resilience in the U.S. economy," he said. But he warned that policy unpredictability can slow down investment and damage international relationships, especially with poorer countries. "There were gigantic tariffs on very poor African countries… I don&#8217;t see what the benefit of that would have been."
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/personal-finance/25/05/45338556/mark-cuban-mocks-maga-merch-being-mostly-made-in-china-says-hes-really-curious-how-trumps-tariffs-will-hit-their-prices-and-availability">Mark Cuban Mocks MAGA Merch Being &#8216;Mostly Made In China&#8217; — Says He&#8217;s &#8216;Really Curious&#8217; How Trump&#8217;s Tariffs Will Hit Their Prices And Availability</a></li>
</ul>
Image Via Shutterstock

MSFT

Bill Gates Slams Trump's Tariffs: We Told China To 'Make Their Own Chips' —And 'They're Making Great Progress,' Warns It's A 'Bad Time To Interject So Much Uncertainty'

Freight Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRGT#NASDAQ">FRGT</a>, &amp;amp, ldquo, Fr8Tech&amp;amp, rdquo, or the &amp;amp, ldquo, Company&amp;amp, rdquo, ))), a logistics management innovation company, offering a diverse portfolio of technology-driven solutions, today announced that it has issued two additional convertible notes for $1 million for purchasing Official Trump ("TRUMP") tokens. This transaction increases Fr8Tech's purchases of TRUMP to $2 million.
&nbsp;
Javier Selgas, Chief Executive Officer of Fr8Tech, commented, "Fr8Tech's continued investment into TRUMP puts us at the intersection of finance and advocacy. It reflects our confidence in the long-term value and utility of blockchain-based digital assets and provides a unique opportunity to champion fair and free trade across the US-Mexico border in the interests of our customers."
&nbsp;
"While Mexican President Claudia Sheinbaum's recent comments that the US and Mexico are ‘…working in the coming days on options to improve our trade balance and advance outstanding issues for the benefit of both countries' is encouraging, we see no reason why a collaborative and constructive framework for fair and free trade cannot be established now. Cross-border trade totaled $840 billion last year, sustained thousands of companies, and supported millions of jobs. We believe both countries have the tools and resources to simultaneously resolve current challenges, such as the flow of fentanyl and other narcotics, and maintain legitimate cross-border commerce," concluded Selgas.
&nbsp;
Fr8Tech's Chief Financial Officer, Don Quinby, added, "We completed the purchase of TRUMP from the initial $1 million convertible notes, and are excited to deepen our cryptocurrency treasury with this second $1 million tranche. As of midday May 11, 2025, the value of our digital assets, including FET tokens and the initial $1 million purchase of TRUMP, was approximately $10.7 million."

FRGT

Freight Tech Firm Doubles Down on TRUMP Token, Invests $2M Amid Crypto and Trade Push

GLD moves 0.8% higher on a down day for the broad market
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/09225627/Screenshot-2025-05-09-at-6.56.03%E2%80%AFPM-1018x1024.png" alt="" class="wp-image-12743" /></figure>
SPDR Gold Trust (GLD) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.&nbsp;
Today, at 10:14 AM on May 9th, a significant trading signal occurred for SPDR Gold Trust (GLD) as it demonstrated a Power Inflow at a price of $306.16. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in GLDs stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in GLDs stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock&#8217;s overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for GLD, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like <a href="https://tradepulse.net/?utm_source=benzinga&amp;utm_medium=article&amp;utm_campaign=brand_awareness_apr2025">https://tradepulse.net/?utm_source=benzinga&amp;utm_medium=article&amp;utm_campaign=brand_awareness_apr2025</a>, which are responsible for parts of the data within this article. 
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved
After Market Close UPDATE:
The price at the time of the Power Inflow was $306.16. The returns on the High price ($308.56) and Close price ($306.84) after the Power Inflow are respectively 0.8% and 0.2%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite.
Disclaimer: Past Performance is not indicative of future performance.

Equities

WIIM

Technicals

Opinion

Signals

Trading Ideas

SPDR Gold Trust Shares Rise After Key Trading Signal

U.S. stocks settled lower on Friday, with the Dow Jones index falling more than 100 during the session.
U.S. major indices also closed lower last week, with the S&amp;P 500 falling about 0.5% and the Nasdaq down around 0.3%. The Dow also declined almost 0.2% in the week.
Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements. Even when it comes to one single stock, analyst ratings and price targets can vary widely, leaving investors confused about which analyst&#8217;s opinion to trust.
Benzinga&#8217;s Analyst Ratings API is a collection of the highest-quality stock ratings curated by the Benzinga news desk via direct partnerships with major sell-side banks. Benzinga displays overnight ratings changes on a daily basis three hours prior to the U.S. equity market opening. Data specialists at investment dashboard provider Toggle.ai recently uncovered that the analyst insights Benzinga Pro subscribers and Benzinga readers regularly receive can successfully be used as trading indicators to outperform the stock market.
Top Analyst Picks: Fortunately, any Benzinga reader can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. One of the ways traders can sort through Benzinga&#8217;s extensive database of analyst ratings is by analyst accuracy. Here&#8217;s a look at the most recent stock picks from each of the five most accurate Wall Street analysts, according to Benzinga <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock</a> Ratings.
Analyst: Doug Anmuth
<ul class="wp-block-list">
<li>Analyst Firm: JP Morgan</li>
<li>Ratings Accuracy: 86%</li>
<li>Latest Rating: Maintained a Neutral rating on Pinterest, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) and raised the price target from $30 to $35 on May 9. This analyst sees around 15% upside in the stock.</li>
<li>Recent News: On May 8, Pinterest reported better-than-expected first-quarter sales results and issued second-quarter sales guidance with its midpoint above estimates.</li>
</ul>
Analyst: Jay McCanless
<ul class="wp-block-list">
<li>Analyst Firm: Wedbush</li>
<li>Ratings Accuracy: 86%</li>
<li>Latest Rating: Maintained a Neutral rating on Rocket Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>) and cut the price target from $13 to $12 on May 9. This analyst sees around 4% surge in the stock.</li>
<li>Recent News: On May 8, Rocket Companies posted in-line earnings for the first quarter.</li>
</ul>
Analyst: Lloyd Walmsley 
<ul class="wp-block-list">
<li>Analyst Firm: UBS</li>
<li>Ratings Accuracy: 86%</li>
<li>Latest Rating: Maintained a Buy rating on Uber Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) and increased the price target from $103 to $107 on May 8. This analyst sees around 24% upside in the stock.</li>
<li>Recent News: On May 7, Uber Technologies reported worse-than-expected first-quarter sales results.</li>
</ul>
Analyst: Alexander Paris
<ul class="wp-block-list">
<li>Analyst Firm: Barrington Research</li>
<li>Ratings Accuracy: 85%</li>
<li>Latest Rating: Maintained an Outperform rating on Universal Technical Institute, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UTI#NYSE">UTI</a>) and raised the price target from $35 to $36 on May 8. This analyst sees around 10% upside in the stock.</li>
<li>Recent News: On May 7, Universal Technical Institute reported better-than-expected second-quarter financial results and raised its FY25 sales guidance above estimates.</li>
</ul>
Analyst: Josh Sullivan
<ul class="wp-block-list">
<li>Analyst Firm: Benchmark</li>
<li>Ratings Accuracy: 85%</li>
<li>Latest Rating: Maintained a Buy rating on Kratos Defense &amp; Security Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTOS#NASDAQ">KTOS</a>) and boosted the price target from $38 to $40 on May 8. This analyst sees around 16% upside in the stock.</li>
<li>Recent News: On May 7, Kratos Defense &amp; Security posted upbeat quarterly earnings.</li>
</ul>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45315727/top-3-industrials-stocks-that-may-collapse-in-may">Top 3 Industrials Stocks That May Collapse In May</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

KTOS

PINS

UBER

5 Stock Picks Last Week From Wall Street's Most Accurate Analysts

CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) reported quarterly earnings of $0.27 per share which beat the analyst consensus estimate of $0.12 by 125 percent. This is a 58.82 percent increase over earnings of $0.17 per share from the same period last year. The company reported quarterly sales of $50.92 million which beat the analyst consensus estimate of $30.84 million by 65.11 percent. This is a 22.80 percent increase over sales of $41.46 million the same period last year.

CTMX

CytomX Therapeutics Q1 EPS $0.27 Beats $0.12 Estimate, Sales $50.92M Beat $30.84M Estimate

CytomX Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>), a leader in the field of masked, conditionally activated biologics, today announced positive interim Phase 1 data for its EpCAM PROBODY&#xAE; ADC candidate, CX-2051, in advanced, late-line CRC. The data are as of an April 7th 2025 data cutoff from the ongoing CTMX-2051-101 Phase 1 study.
"EpCAM is a high potential and broadly expressed cancer target that has been challenging to drug historically due to expression on normal tissues. We believe we have broken important new ground with our data announced today, which show potential for markedly improved outcomes for CRC patients," said Sean McCarthy, D. Phil, chief executive officer and chairman of CytomX. "CX-2051 is showing impressive, durable anti-tumor activity in late line metastatic CRC, an area of high unmet need and a very difficult tumor to treat. Furthermore, CX-2051 has been generally well tolerated, highlighting the power of CytomX PROBODY&#xAE; masking technology."
Dr. McCarthy added, "Importantly, we believe these results validate EpCAM as an oncology target and unlock a broad development opportunity for CX-2051 in CRC and potentially many other cancer types where EpCAM is expressed. We are excited to rapidly advance CX-2051 for the benefit of CRC patients and to explore the full potential of this novel ADC."

CytomX Reports Early Data for New Colon Cancer Drug Targeting EpCAM

HC Wainwright &amp; Co. analyst Kevin Dede reiterates BitFuFu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUFU#NASDAQ">FUFU</a>) with a Buy and maintains $7 price target.

Reiteration

FUFU

HC Wainwright & Co. Reiterates Buy on BitFuFu, Maintains $7 Price Target

Guidance

SDRL

Seadrill Affirms FY2025 Sales Guidance of $1.30B-$1.36B vs $1.36B Est

Seadrill Q1 EPS $(0.23) Misses $0.60 Estimate, Sales $335.00M Beat $334.54M Estimate

<ul>
<li>Additionally, the complaint seeks to enjoin Liquidia from commercializing YUTREPIA (treprostinil) inhalation powder if approved by the U.S. Food and Drug Administration (FDA) to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).</li>
<li>The ‘782 patent, which issued on June 14, 2022, arises out of the same patent family as U.S. Patent No. 10,716,793 (the ‘793 patent) and claims the same general method of administering inhaled treprostinil to pulmonary hypertension patients. As disclosed in July 2022, the ‘793 patent was held to be invalid in a proceeding before the Patent Trial and Appeal Board (PTAB). The PTAB's decision was affirmed by the&nbsp;U.S. Court of Appeals for the Federal Circuit&nbsp;in&nbsp;December 2023. The United States Supreme Court&nbsp;rejected UTHR's petition for a writ of certiorari, thereby upholding PTAB's decision which found that all claims of the ‘793 patent are unpatentable due to prior art as final and not subject to further appeal.</li>
<li>UTHR is currently not seeking any injunction against the FDA to prevent final approval of the New Drug Application (NDA) for YUTREPIA. As previously announced, the FDA set a Prescription Drug User Fee Act (PDUFA) goal date of May 24, 2025.</li>
</ul>

Biotech

Health Care

Legal

LQDA

UTHR

United Therapeutics Corporation Filed A Complaint On May 9, 2025, In The U.S. District Court For The Middle District Of North Carolina Against Liquidia Alleging Infringement Of U.S. Patent No. 11,357,782.

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.walkerdunlop.com%2F&amp;esheet=54252815&amp;newsitemid=20250512455389&amp;lan=en-US&amp;anchor=Walker+%26amp%3B+Dunlop%2C+Inc.&amp;index=1&amp;md5=1495e66b29aae4d37b0eaffd41071612">Walker &amp; Dunlop, Inc.</a> is celebrating the ground breaking of Parkside 5, the fifth and final phase of the Parkside at Old Town development, a 99-unit community located on the former Cabrini-Green public housing site in Chicago's Near North Side.
&nbsp;
&nbsp;
Parkside 5 Groundbreaking. (Photo courtesy of Holsten Real Estate Development Corp.)
The Walker &amp; Dunlop affordable housing team, led by <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.walkerdunlop.com%2Fabout%2Fpeople%2Fjen-erixon&amp;esheet=54252815&amp;newsitemid=20250512455389&amp;lan=en-US&amp;anchor=Jennifer+Erixon&amp;index=2&amp;md5=3497114b7444654b189ea95a93a6c8ae">Jennifer Erixon</a>, syndicated Low Income Housing Tax Credits (LIHTC) and Illinois Donation Tax Credits on behalf of the client, Holsten Real Estate Development Corporation. Walker &amp; Dunlop Affordable Equity syndicated the equity to JP Morgan, resulting in $22.6 million of equity to support the development. In addition to syndicating the credits, JP Morgan is also providing a construction loan for the project.
The funding will support the construction of a mix of market-rate and affordable units, with 37 of the units benefiting from a 20-year Section 8 Housing Assistance Payment (HAP) contract. These affordable units will be reserved for households earning 50% and 60% of the area median income (AMI) or less. "We are proud to support the continued revitalization of the Near North Side, helping to bring much-needed affordable housing options to the community while contributing to the broader transformation of the former Cabrini-Green site," said Jennifer Erixon, senior managing director of Affordable Equity Originations at Walker &amp; Dunlop. "Our partners at Holsten have allowed us to provide a valuable solution that meets our shared goals."
Parkside 5 will feature three 3-story walk-up buildings and an 8-story mid-rise structure with townhome units at its base. Planned amenities include a community room, fitness center, and onsite social services for residents. Additionally, a playground, and dog park, will be open to the community to position Parkside 5 as a vibrant, inclusive space for its residents and neighbors. The development will complement the existing phases of the Parkside at Old Town project, a key piece in the ongoing revitalization of the historic neighborhood.

Final Phase of Chicago's Cabrini-Green Revamp Breaks Ground With 99 New Homes, Backed by Walker & Dunlop

Canlan Ice Sports (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ICE#TSX">ICE</a>) reported quarterly earnings of $0.32 per share. This is unchanged from the same period last year. The company reported $27.98 million in sales this quarter. This is a 6.85 percent increase over sales of $26.19 million the same period last year.

TSX:ICE

Canlan Ice Sports Q1 EPS $0.32, Same YoY, Sales $27.98M Up From $26.19M YoY

<ul>
<li>Multiple doses of APG808 resulted in rapid suppression of FeNO, a biomarker of Type 2 inflammation associated with exacerbations in asthma, with a robust maximal FeNO decrease from baseline of 53%</li>
<li>APG808 demonstrated the potential for durable disease control in asthma with sustained FeNO decrease from baseline of 50% at 12 weeks</li>
<li>APG808's optimized formulation and potential best-in-class pharmacokinetic (PK) profile, combined with robust and sustained FeNO suppression through 12 weeks, support the potential for transformative dosing every 2-months or longer, compared to the current biweekly standard of care</li>
<li>APG808 was well tolerated with a favorable safety profile consistent with the anti-IL-4Rα class</li>
<li>Phase 1b proof-of-concept data validates Apogee's approach to designing potentially best-in-class biologics and builds on Apogee's track record of execution</li>
</ul>

APGE

Apogee Therapeutics Released Interim Data From Its Phase 1b Trial Of APG808, A Novel Half-life Extended IL-4Rα Antibody, In Patients With Mild-to-moderate Asthma

Vertical Aerospace ("Vertical") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVTL#NYSE">EVTL</a>) today announced it is developing a hybrid-electric vertical-take-off-and landing (VTOL) variant of its VX4 aircraft, expanding range and payload capabilities to unlock new market opportunities within the already sizable $1TR1 total addressable urban air mobility market.
&nbsp;
&nbsp;
Vertical's second-generation hybrid-propulsion system, which has been in development for 18 months at the Vertical Energy Centre
Vertical's hybrid-electric strategy builds on its all-electric VX4 and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fvertical-aerospace.com%2Fwp-content%2Fuploads%2F2024%2F11%2FVertical-Aerospace-Launches-Flightpath-2030-a-strategy-to-pioneer-electric-aviation.pdf&amp;esheet=54252992&amp;newsitemid=20250512888129&amp;lan=en-US&amp;anchor=Flightpath+2030+strategy&amp;index=1&amp;md5=4ff01c56d06d0d49334fe4ce9c9c11f4">Flightpath 2030 strategy</a>, enabling new potential applications in defence, logistics and commercial sectors including air ambulance services, which require longer range and higher payload than current eVTOL platforms can deliver.
Vertical's second-generation hybrid-propulsion system, which has been in development for 18 months at the Vertical Energy Centre, will be retrofitted into one of the company's VX4 full scale prototypes and is expected to commence flight testing in Q2 2026.

EVTL

Vertical Aerospace Unveils Hybrid Air Taxi to Boost Range, Targeting $1T Urban Air Mobility Market

<ul>
<li>Phase 2 APEX trial of APG777 in atopic dermatitis advancing with interim Part A 16-week data expected in mid-2025 and Part B actively enrolling</li>
<li>First patient dosed in Phase 1b trial of APG777 in mild-to-moderate asthma with readout expected in 1H 2026</li>
<li>APG279 on track to initiate Phase 1b head-to-head trial vs DUPIXENT in 2025 with readout expected in 2H 2026</li>
<li>Positive interim Phase 1b readout of APG808 in patients with mild-to-moderate asthma demonstrated rapid, robust and sustained suppression of FeNO, a biomarker of Type 2 inflammation that is associated with exacerbations in asthma</li>
</ul>

Apogee Therapeutics Cash, Cash Equivalents And Marketable Securities Were $681.4M As Of March 31, 2025 That Supports Runway Into Q1 2028

Allot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLT#NASDAQ">ALLT</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.05) by 140 percent. This is a 166.67 percent increase over losses of $(0.03) per share from the same period last year. The company reported quarterly sales of $23.20 million which beat the analyst consensus estimate of $20.20 million by 14.85 percent. This is a 5.98 percent increase over sales of $21.89 million the same period last year.

ALLT

Allot Q1 Adj. EPS $0.02 Beats $(0.05) Estimate, Sales $23.20M Beat $20.20M Estimate

Press Releases

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025

Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591

Management

Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care

Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications

Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio

Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio

ATOS

Alector

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

C4 Therapeutics

Coherus BioSciences

Coya Therapeutics

Editas Medicine

Enanta Pharmaceuticals, Inc. - Common Stock

Enanta Pharma

EXoZymes

Fate Therapeutics

Genelux

HilleVax

Immunic

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals

Kyverna Therapeutics, Inc. - Common Stock

Kyverna Therapeutics

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics

Lyell Immunopharma

ProKidney Corp. - Class A Ordinary Shares

ProKidney

RAPT Therapeutics

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences

Tango Therapeutics

Tonix Pharmaceuticals Holding Corp. - Common Stock

Comments

Atossa Therapeutics

Notizie

Ultime notizie per Atossa Therapeutics (NASDAQ:ATOS) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO